
Becton, Dickinson and Company Investor Relations Material
Latest events

Q2 2025
Becton, Dickinson and Company
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Becton, Dickinson and Company
Access all reports
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's principal businesses are based upon its expertise in the areas of vascular access devices (VADs), hemostasis systems and technologies, bioscience research tools for cell culture reagents and assays, transfusion technologies through a majority ownership interest in C.R. Bard Incorporated; Point-of-care testing instruments covering blood collection with red cell alloimmunization detection capability; transcutaneous immunoglobulin (Ig) replacement therapy; nutritionals.
Key slides for Becton, Dickinson and Company


Q2 2025
Becton, Dickinson and Company


Q1 2025
Becton, Dickinson and Company
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
BDX
Country
🇺🇸 United States